The People Paradox: Why the Radiopharma Revolution Will Be Won by Talent, Not Just Technology
By Byron Fitzgerald, Founder, ProGen Search The radiopharmaceutical sector is in the throes of a legitimate gold rush. Validated by the blockbuster commercial success of Novartis’s Pluvicto®, a torrent of capital is flooding the market, with projections soaring past $26 billion by 2031. This financial fervor has ignited a series of multi-billion-dollar acquisitions, with giants […]